{
    "nctId": "NCT03991260",
    "briefTitle": "99mTc-ADAPT6-based HER2 Imaging in Breast Cancer",
    "officialTitle": "SPECT Imaging of HER2 Expression in Breast Cancer Using Technetium-99m-labelled ADAPT6",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Gamma camera-based whole-body 99mTc-ADAPT6 uptake value (%)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject is \\> 18 years of age\n2. Diagnosis of primary breast cancer with possible lymph node metastases\n3. Availability of results from HER2 status previously determined on material from the primary tumor, either\n\n   1. HER2-positive, defined as a DAKO HercepTest\u2122 score of 3+ or FISH positive or\n   2. HER2-negative, defined as a DAKO HercepTest\u2122 score of 0 or 1+; or else if 2+ then FISH negative\n4. Volumetrically quantifiable tumour lesions on CT or MRI, with at least one lesion \\> 1.0 cm in greatest diameter outside of the liver and kidneys\n5. Hematological, liver and renal function test results within the following limits:\n\n   * White blood cell count: \\> 2.0 x 10\\^9/L\n   * Haemoglobin: \\> 80 g/L\n   * Platelets: \\> 50.0 x 10\\^9/L\n   * ALT, ALP, AST: =\\< 5.0 times Upper Limit of Normal\n   * Bilirubin =\\< 2.0 times Upper Limit of Normal\n   * Serum creatinine: Within Normal Limits\n6. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination\n7. Subject is capable to undergo the diagnostic investigations to be performed in the study\n\n11. Informed consent\n\nExclusion Criteria:\n\n1. Second, non-breast malignancy\n2. Active current autoimmune disease or history of autoimmune disease\n3. Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)\n4. Known HIV positive or chronically active hepatitis B or C\n5. Administration of other investigational medicinal product within 30 days of screening\n6. Ongoing toxicity \\> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}